Vertex Pharmaceuticals, Inc. (VRTX) Stock Forecast & Predictions

Vertex Pharmaceuticals, Inc. VRTX: $187.85

50 Northern Ave, Boston, Massachusetts, US. | Sector: Manufacturing | Exchange: NASDAQ/NGS (GLOBAL SELECT MARKET) | Web: www.vrtx.com

  • Market Cap$48.63B
  • Change (52 Weeks)-35.95%
  • Low (52 Weeks)$185.64
  • Vertex Pharmaceuticals, Inc. (VRTX) Forecast Based on Technical Analysis


    Neutral
    Based on 16 Technical Indicators where 0.00% are on Buy, 50.00% on Sell, and 50.00% Neutral.

    According to the market data, Vertex Pharmaceuticals, Inc. (VRTX) stock price is $187.85 and the 52 weeks low is $185.64, which means the Vertex Pharmaceuticals, Inc. stock price is down -35.95% in the last 12 months.

    Vertex Pharmaceuticals, Inc. (VRTX) Stock Price is not Trending currently as per the Weekly Chart, which means the price may range between specific high and low levels for the next few months, unless some significant changes take place in the market performance or news.

    Technical Indicators are algorithms that are used mostly by Technical traders to predict the price action of a stock.

    Based on our analysis of 16 technical indicators, 0.00% are indicating that VRTX Stock price might rise further, 50.00% indicating that VRTX Stock price might fall, and 50.00% are in a neutral position.

    Based on these technical algorithms, overall VRTX stock price has a Neutral Signal, which means the stock price has the potential to move either up or down, depending on the nature of consolidating market phase, since majority of indicators are providing a neutral signal.

    Vertex Pharmaceuticals, Inc. (VRTX) Stock Forecast By Analysts


    Strong Buy
    Analysts Recommendations for Vertex Pharmaceuticals, Inc. (VRTX) is based on 32 Institutional Analyst Ratings where 50.00% are on Strong Buy, 34.38% on Moderate Buy, 15.63% remains on Hold, 0.00% are on Moderate Sell and 0.00% are on Strong Sell.

    Out of 32 Institutional Analysts, majority recommended VRTX stock as Strong Buy. Since most investors and traders follow analyst ratings closely, this can be a potentially driving factor for the future stock price of Vertex Pharmaceuticals, Inc..

    Vertex Pharmaceuticals, Inc. (VRTX) Stock Price Prediction By Analysts


    HighLowAverage
    $347.55$202.00$268.16
    $268.1642.75% Upside
    Updated: 2021-06-18 00:00:00

    The Average Price target for VRTX set by the institutional analysts is $268.16 where High Estimate is $347.55, Median $280.5 and Low $202.00.

    The average price target for VRTX by Institutional Analysts is $268.16, which is 42.75% Upside from the current price. So according to the Institutional Analysts, VRTX Stock might be a bit undervalued at this stage and there’s potential for upside.

    However, although Institutional Analysts set their price targets after extensive research, they’re not always correct. After all, the market is mostly driven by investors speculation and emotion than just concrete numbers.

    Vertex Pharmaceuticals, Inc. (VRTX) Stock Forecast Based on Investor Sentiment


    Very Positive

    Based on 433,085 investor portfolio.

    Our algorithm has analysed 433,085 investor portfolio with VRTX stock holdings and found that 99.50% of them are bullish. Which means the Investor Sentiment is mostly Very Positive.

    This shows most investors are very optimistic about VRTX and holding their positions hoping for a further rise in the stock price and more profit.

    Vertex Pharmaceuticals, Inc. (VRTX) Stock Forecast Based on News Sentiment


    Neutral
    Based on 14 articles published Last Week, where 50.00% are Bullish and 50.00% are Bearish.

    According to the news articles published last week, journalists and bloggers had a mixed sentiment of VRTX consisting of positive and negative, it shows that Vertex Pharmaceuticals, Inc. had a neutral news coverage.

    Neutral news coverage usually doesn't affect short-term price of a stock, so VRTX stock price most likey won't have any reaction to last weeks news coverage.

    Vertex Pharmaceuticals, Inc. (VRTX) Stock Forecasts By Institutional Analysts


    Analyst
    Recommendation
    Action
    Truist SecuritiesBuyMaintained
    SVB LeerinkMarket PerformMaintained
    Piper SandlerOverweightMaintained
    StifelBuyMaintained
    RBC CapitalOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    Goldman SachsBuyMaintained
    CitigroupBuyMaintained
    Cantor FitzgeraldOverweightMaintained
    BarclaysOverweightMaintained
    BairdOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    Morgan StanleyEqual-WeightMaintained
    BairdOutperformUpgraded
    SVB LeerinkMarket PerformMaintained
    Piper SandlerOverweightMaintained
    Credit SuisseOutperformMaintained
    BMO CapitalOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    RBC CapitalOutperformUpgraded
    BernsteinOutperformInitiated
    SVB LeerinkMarket PerformMaintained
    Credit SuisseOutperformMaintained
    UBSBuyInitiated
    Morgan StanleyEqual-WeightMaintained
    SVB LeerinkMarket PerformMaintained
    Morgan StanleyEqual-WeightMaintained
    SVB LeerinkMarket PerformMaintained
    SVB LeerinkMarket PerformMaintained
    HC Wainwright & Co.BuyMaintained
    Cantor FitzgeraldOverweightMaintained
    Credit SuisseOutperformMaintained
    Morgan StanleyEqual-WeightDowngraded
    SunTrust Robinson HumphreyBuyMaintained
    CitigroupBuyMaintained
    Argus ResearchBuyMaintained
    CitigroupBuyMaintained
    SVB LeerinkMarket PerformMaintained
    StifelBuyMaintained
    OppenheimerOutperformMaintained
    Morgan StanleyOverweightMaintained
    JMP SecuritiesMarket OutperformMaintained
    HC Wainwright & Co.BuyMaintained
    GuggenheimBuyMaintained
    CFRABuyMaintained
    BMO CapitalOutperformMaintained
    RBC CapitalSector PerformDowngraded
    Morgan StanleyOverweightMaintained
    Cantor FitzgeraldOverweightReiterated
    Stifel NicolausBuyMaintained
    RBC CapitalOutperformMaintained
    Morgan StanleyOverweightMaintained
    Credit SuisseOutperformMaintained
    CFRABuyMaintained
    BairdNeutralDowngraded
    B of A SecuritiesBuyMaintained
    OppenheimerOutperformMaintained
    PiperJaffrayOverweightMaintained
    JP MorganOverweightMaintained
    Bank of AmericaBuyReiterated
    Cantor FitzgeraldOverweightMaintained
    SunTrust Robinson HumphreyBuyInitiated
    Stifel NicolausBuyMaintained
    Piper JaffrayOverweightMaintained
    Morgan StanleyOverweightMaintained
    CitigroupBuyMaintained
    Morgan StanleyOverweightMaintained
    Goldman SachsBuyReiterated
    Stifel NicolausBuyMaintained
    Piper JaffrayOverweightMaintained
    NeedhamHoldDowngraded
    Credit SuisseOutperformMaintained
    Credit SuisseOutperformInitiated
    Evercore ISI GroupIn-LineInitiated
    William BlairOutperformUpgraded
    SVB LeerinkMarket PerformDowngraded
    OppenheimerOutperformMaintained
    CitigroupBuyMaintained
    Raymond JamesMarket PerformDowngraded
    Morgan StanleyOverweightMaintained
    H.C. WainwrightBuyUpgraded
    Raymond JamesOutperformMaintained
    BMO CapitalOutperformMaintained
    Cantor FitzgeraldOverweightInitiated
    CitigroupBuyMaintained
    UBSNeutralMaintained
    Morgan StanleyOverweightMaintained
    Morgan StanleyOverweightMaintained
    Maxim GroupBuyMaintained
    JMP SecuritiesMarket OutperformMaintained
    Credit SuisseOutperformMaintained
    Morgan StanleyOverweightMaintained
    BMO CapitalOutperformMaintained
    BarclaysOverweightMaintained
    Bank of AmericaBuyMaintained
    Bank of AmericaBuyUpgraded
    Deutsche BankBuyInitiated
    DA DavidsonBuyInitiated
    RBC CapitalOutperformInitiated
    Raymond JamesOutperformUpgraded
    Janney CapitalBuyUpgraded
    Cowen & Co.OutperformUpgraded
    CitigroupBuyMaintained
    BarclaysOverweightUpgraded
    JefferiesBuyInitiated
    NeedhamBuyUpgraded
    OppenheimerOutperformUpgraded
    BMO CapitalOutperformUpgraded
    JMP SecuritiesMarket OutperformUpgraded
    OppenheimerPerformInitiated
    BarclaysEqual-WeightDowngraded
    Janney CapitalNeutralInitiated
    William BlairMarket PerformDowngraded
    H.C. WainwrightNeutralDowngraded
    JefferiesBuyMaintained
    JefferiesBuyMaintained
    Raymond JamesMarket PerformInitiated
    Morgan StanleyOverweightMaintained
    Goldman SachsNeutralDowngraded
    Credit SuisseOutperformMaintained
    BMO CapitalMarket PerformInitiated
    Leerink SwannOutperformMaintained
    Leerink SwannOutperformInitiated
    JefferiesBuyUpgraded
    BarclaysOverweightMaintained
    JP MorganOverweightMaintained
    BarclaysOverweightMaintained
    Credit SuisseOutperformInitiated
    Stifel NicolausBuyInitiated
    H.C. WainwrightBuyUpgraded
    Morgan StanleyOverweightUpgraded
    ArgusBuyUpgraded
    BarclaysOverweightUpgraded
    JefferiesHoldInitiated
    JMP SecuritiesMarket OutperformMaintained
    Leerink SwannOutperformMaintained
    Bank of AmericaNeutralMaintained
    RBC CapitalOutperformMaintained
    CitigroupBuyMaintained
    Canaccord GenuityBuyInitiated
    Maxim GroupHoldMaintained
    Credit SuisseBuyMaintained
    CitigroupBuyMaintained
    BTIG ResearchBuyInitiated
    BarclaysEqual-weightInitiated
    JMP SecuritiesMarket OutperformMaintained
    JMP SecuritiesMarket PerformMaintained
    PiperJaffrayOverweightUpgraded
    GuggenheimBuyInitiated
    Deutsche BankBuyMaintained
    Deutsche BankBuyMaintained
    Goldman SachsBuyUpgraded
    OppenheimerMarket PerformInitiated
    UBSBuyMaintained
    H.C. WainwrightNeutralDowngraded
    CitigroupBuyMaintained
    UBSBuyUpgraded
    Goldman SachsNeutralMaintained
    Summer StreetNeutralDowngraded
    OppenheimerOutperformInitiated
    UBSNeutralDowngraded
    WunderlichBuyInitiated
    UBSBuyMaintained
    Morgan StanleyEqual-WeightMaintained
    Goldman SachsNeutralUpgraded
    Deutsche BankBuyMaintained
    CitigroupBuyMaintained
    Canaccord GenuityBuyUpgraded
    Canaccord GenuityHoldInitiated
    JP MorganOverweightMaintained
    LazardNeutralDowngraded
    BarclaysOverweightMaintained
    Janney CapitalBuyInitiated
    Deutsche BankBuyMaintained
    ArgusDowngraded
    Credit SuisseNeutralDowngraded
    Goldman SachsSellDowngraded
    Credit SuisseOutperformMaintained
    Deutsche BankBuyInitiated
    ArgusBuyInitiated
    UBSBuyMaintained
    PiperJaffrayNeutralDowngraded
    Goldman SachsNeutralMaintained
    CitigroupBuyMaintained
    Bank of AmericaBuyMaintained
    JP MorganOverweightUpgraded
    Goldman SachsNeutralMaintained
    Morgan StanleyEqual-WeightUpgraded
    Brean CapitalBuyUpgraded
    ISI GroupBuyUpgraded
    UBSNeutralMaintained
    UBSNeutralMaintained
    Morgan StanleyUnderweightDowngraded
    Bank ofericaBuyMaintained

    Vertex Pharmaceuticals, Inc. (VRTX) Stock Earning Per Share (EPS) Forecast / Estimate


    $2.716
    The average consensus EPS for VRTX is $2.716 with a high estimate of $3.213 and Low of $1.607 for the period 2021-09-30 and based on 23 Institutional Analysts.

    Last Quarter


    Actual
    Estimate
    Date
    $2.98$2.74261680000000042021-03-31


    Earning Per Share (EPS) History


    Actual
    Estimate
    Date
    $$2.35711800000000032021-06-30
    $2.98$2.74261680000000042021-03-31
    $2.51$2.64219780000000042020-12-31
    $2.64$2.38938062020-09-30
    $2.61$2.1154292020-06-30
    $2.56$1.88192020-03-31
    $1.7$1.23162962019-12-31
    $1.23$1.17203099999999982019-09-30
    $1.26$1.08849300000000022019-06-30
    $1.14$0.99256199999999992019-03-31
    $1.3$1.08353582018-12-31
    $1.09$1.03923722018-09-30
    $0.94$0.7618892018-06-30
    $0.76$0.64106999999999992018-03-31
    $0.61$0.54042662017-12-31
    $0.53$0.31886222017-09-30
    $0.39$0.359552017-06-30
    $0.41$0.40155362017-03-31
    $0.35$0.292831800000000032016-12-31
    $0.16$0.183092016-09-30
    $0.24$0.210232199999999982016-06-30
    $0.09$0.29204642016-03-31
    $0.17$0.171788399999999982015-12-31
    $-0.13$-0.28935362015-09-30
    $-0.54$-0.58945799999999992015-06-30
    $-0.83$-0.76431662015-03-31
    $-0.74$-0.66382622014-12-31
    $-0.72$-0.6319922014-09-30
    $-0.68$-0.7290452014-06-30
    $-1$-0.69621119999999992014-03-31
    $0.19$-0.55964342013-12-31
    $-0.54$-0.35033942013-09-30
    $-0.26$-0.19382013-06-30
    $-0.11$-0.186996599999999992013-03-31
    $-0.09$-0.08162012-12-31
    $-0.27$0.201962012-09-30
    $0.06$0.58714262012-06-30
    $0.43$0.57122012-03-31
    $0.74$0.71760062011-12-31
    $1.02$0.21866762011-09-30

    What is Analyst Ratings & Price Targets?

    The analysts provide Buy, Sell or Hold ratings after extensive research of a companies financial reports, listening to conference calls and some of them even get in contact with upper management of the company to get an overall picture of operation.

    Although institutional Analyst’s are not always correct, their ratings are followed by millions of traders around the world and they can heavily influence trading activities for a company.

    As a retail investor, going through analyst ratings will instantly provide you an idea if the stock is worth buying. Top Analysts also provide their price targets. It’s a prediction of where the stock price might go based on their analysis.

    The best way to analyze price targets is to combined average price targets of major analysts. If the average price target is much higher than the current price of the stock, then the probability of a stock going up is also high.

    What is Technical Analysis?

    Technical Analysis refers to analyzing a stock's price over a period of time. In the financial market, past price patterns are one of the strongest indicators of an asset's future performance.

    In easier terms, millions of traders use Live Charts to watch the stock prices, it is actually a single source of truth for most traders. When a stock's price reaches a significant price level/pattern in the chart, millions of traders take buy/sell positions from those levels.

    As a regular investor, one of the easiest ways to check technical analysis of a stock is through Technical Indicators. Technical Indicators are programmed algorithms that monitor price changes in the Charts and indicate Buy/Sell based on market conditions.

    Some Technical Indicators can be very powerful (e.g SMA) and some can be pretty useless. Stock research tools like iTradely heavily simplify the technical analysis process for the investors by showing Buy/Sell/Neutral ratings combined from 17 powerful technical indicators, all in one page.

    What is Earnings Per Share (EPS) and Why is it Important?

    EPS, or Earning Per Share, can tell a lot about a stock’s performance. It’s calculated by dividing a company’s profit by the number of outstanding shares of its common stocks.

    In layman’s term, earnings is an indicator of a company’s profitability. Higher the earnings, the more profitable a company is.
    Some traders pick stocks solely based on EPS or earnings Analysis, it is a very powerful indicator of a stock’s price.

    Before you buy a stock, check the company’s earnings History and Surprises. A Surprise happens when a company reports a much higher or lower actual earnings/EPS than the forecasted earnings/EPS.

    If a company reports higher EPS surprises consistently, analysts keep raising their estimates, traders become more confident in the company, driving the share price higher.

    What is Stock Sentiment?

    Stock Sentiment refers to how people speculating about the stock or what kind of trading position investors are often taking.

    There are different kinds of sentiments you can find online for a company, this includes Investor Sentiment (Percentage of investors buying or selling), News Sentiment (Is the company getting positive or negative impressions from the Press?), Social Sentiment (The overall trends about the company in social media, is it negative or positive?).